211 related articles for article (PubMed ID: 22801851)
21. Dramatic regression of persistent tunica vasculosa lentis associated with retinopathy of prematurity following treatment with intravitreal bevacizumab.
Goldman DR; Baumal CR
J Pediatr Ophthalmol Strabismus; 2013 Jun; 50 Online():e27-9. PubMed ID: 24601434
[TBL] [Abstract][Full Text] [Related]
22. Acute contraction of the proliferative membrane after an intravitreal injection of bevacizumab for advanced retinopathy of prematurity.
Honda S; Hirabayashi H; Tsukahara Y; Negi A
Graefes Arch Clin Exp Ophthalmol; 2008 Jul; 246(7):1061-3. PubMed ID: 18320201
[TBL] [Abstract][Full Text] [Related]
23. Intravitreal bevacizumab following laser therapy for severe retinopathy of prematurity.
Erol N; Gürsoy H; Sahin A; Basmak H
J Pediatr Ophthalmol Strabismus; 2010 Aug; 47 Online():e1-4. PubMed ID: 21158371
[TBL] [Abstract][Full Text] [Related]
24. Prolonged follow-up period following intravitreal bevacizumab injection for stage 3+ retinopathy of prematurity.
de Klerk TA; Park DY; Biswas S
Eye (Lond); 2013 Oct; 27(10):1218. PubMed ID: 23846376
[No Abstract] [Full Text] [Related]
25. Different refractive errors in triplets with retinopathy of prematurity treated with bevacizumab.
Tseng CC; Chen SN; Hwang JF; Lin CJ
J Pediatr Ophthalmol Strabismus; 2012 Aug; 49 Online():e41-3. PubMed ID: 22881829
[TBL] [Abstract][Full Text] [Related]
26. Combined intravitreal bevacizumab injection and zone I sparing laser photocoagulation in patients with zone I retinopathy of prematurity.
Kim J; Kim SJ; Chang YS; Park WS
Retina; 2014 Jan; 34(1):77-82. PubMed ID: 23807184
[TBL] [Abstract][Full Text] [Related]
27. Intravitreal bevacizumab for the treatment of retinopathy of prematurity: a case report.
Flavahan PW; Lavy TE; Wykes W
Scott Med J; 2013 Aug; 58(3):130-2. PubMed ID: 23960050
[TBL] [Abstract][Full Text] [Related]
28. Treatment of type 1 retinopathy of prematurity with intravitreal bevacizumab (Avastin).
Dorta P; Kychenthal A
Retina; 2010 Apr; 30(4 Suppl):S24-31. PubMed ID: 20224475
[TBL] [Abstract][Full Text] [Related]
29. Exudative retinopathy and detachment: a late reactivation of retinopathy of prematurity after intravitreal bevacizumab.
Ittiara S; Blair MP; Shapiro MJ; Lichtenstein SJ
J AAPOS; 2013 Jun; 17(3):323-5. PubMed ID: 23607977
[TBL] [Abstract][Full Text] [Related]
30. Intravitreal injection of bevacizumab (avastin) for treatment of stage 3 retinopathy of prematurity in zone I or posterior zone II.
Mintz-Hittner HA; Kuffel RR
Retina; 2008 Jun; 28(6):831-8. PubMed ID: 18536599
[TBL] [Abstract][Full Text] [Related]
31. Late-onset tractional fibrovascular proliferation post-intravitreal bevacizumab following treatment of retinopathy of prematurity.
Agarwal-Sinha S; Guevara JG; Amin SM
Can J Ophthalmol; 2018 Jun; 53(3):e99-e103. PubMed ID: 29784188
[No Abstract] [Full Text] [Related]
32. Adjunctive effect of intravitreal bevacizumab prior to lens-sparing vitrectomy in aggressive posterior retinopathy of prematurity: a case report.
Sun HJ; Choi KS; Lee SJ
Jpn J Ophthalmol; 2012 Sep; 56(5):476-80. PubMed ID: 22843138
[TBL] [Abstract][Full Text] [Related]
33. Primary intravitreal ranibizumab for high-risk retinopathy of prematurity.
Baumal CR; Goldberg RA; Fein JG
Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):432-8. PubMed ID: 25970863
[TBL] [Abstract][Full Text] [Related]
34. Intravitreal bevacizumab monotherapy for retinopathy of prematurity.
Şahin A; Şahin M; Cingü AK; Çınar Y; Türkcü FM; Yüksel H; Kaya S; Arı Ş; Caça İ
Pediatr Int; 2013 Oct; 55(5):599-603. PubMed ID: 23659781
[TBL] [Abstract][Full Text] [Related]
35. Bevacizumab for retinopathy of prematurity.
Lim LS; Mitchell P; Wong TY
N Engl J Med; 2011 Jun; 364(24):2360; author reply 2361-2. PubMed ID: 21675897
[No Abstract] [Full Text] [Related]
36. Fluorescein angiography of aggressive posterior retinopathy of prematurity treated with intravitreal anti-VEGF in large preterm babies.
Park SW; Jung HH; Heo H
Acta Ophthalmol; 2014 Dec; 92(8):810-3. PubMed ID: 24909062
[No Abstract] [Full Text] [Related]
37. Bevacizumab for retinopathy of prematurity.
Gilbert CE; Zin A; Darlow B
N Engl J Med; 2011 Jun; 364(24):2359-60; author reply 2361-2. PubMed ID: 21675898
[No Abstract] [Full Text] [Related]
38. Pharmacokinetics of bevacizumab and its effects on serum VEGF and IGF-1 in infants with retinopathy of prematurity.
Kong L; Bhatt AR; Demny AB; Coats DK; Li A; Rahman EZ; Smith OE; Steinkuller PG
Invest Ophthalmol Vis Sci; 2015 Jan; 56(2):956-61. PubMed ID: 25613938
[TBL] [Abstract][Full Text] [Related]
39. Intravitreal anti-vascular endothelial growth factor treatment for retinopathy of prematurity: comparison between Ranibizumab and Bevacizumab.
Chen SN; Lian I; Hwang YC; Chen YH; Chang YC; Lee KH; Chuang CC; Wu WC
Retina; 2015 Apr; 35(4):667-74. PubMed ID: 25462435
[TBL] [Abstract][Full Text] [Related]
40. Serum concentrations of vascular endothelial growth factor in an infant treated with ranibizumab for retinopathy of prematurity.
Hoerster R; Muether P; Dahlke C; Mehler K; Oberthür A; Kirchhof B; Fauser S
Acta Ophthalmol; 2013 Feb; 91(1):e74-5. PubMed ID: 22672259
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
